Britannia Life Sciences Inc (BLAB) AI Stock Analysis

• Market Cap: C$15.41M
• Dividend Yield: N/A
• Average Volume (3M): 73.07K
• Price to Earnings (P/E): 0.3
• Beta (1Y): -1.42
• Revenue Growth: -3.93%
• EPS Growth: -575.24%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.07
• Shares Outstanding: 162,254,330
• 10 Day Avg. Volume: 81,691
• 30 Day Avg. Volume: 73,070
• PEG Ratio: -0.81
• Price to Book (P/B): 1.93
• Price to Sales (P/S): 32.95
• P/FCF Ratio: -4.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: C$0.09 ▲(17.50% Upside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is held down primarily by weak financial performance—negative operating/free cash flow and volatile, low-quality earnings signals—despite a recently improved balance sheet. Technicals provide some support due to a positive trend and MACD, but elevated RSI suggests stretched momentum. Valuation contributes modestly negative impact because the negative P/E limits interpretability and no dividend yield is available.

Positive Factors

Improved leverage

The materially reduced debt burden and very low current total debt improve financial flexibility and lower refinancing risk. Over a multi-month horizon this supports sustaining R&D and operating programs without large near-term interest obligations, reducing probability of distress-driven disruption.

Positive trailing ROE

A positive TTM ROE indicates the company can generate returns on shareholders' equity when earnings are favorable. If management stabilizes operations, this suggests a structural ability to translate capital into profits, improving long-term capital efficiency versus loss-making peers.

Historical cash generation capability

Prior episodes of positive operating cash flow demonstrate the underlying business model can generate internal cash under certain conditions. That historical capability reduces structural execution risk and implies management can potentially restore cash generation without sole reliance on external financing.

Negative Factors

Meaningful cash burn

Sustained negative operating and free cash flow requires ongoing external funding or dilution to maintain operations. Over a 2–6 month horizon this increases financing risk, can constrain investment in clinical programs, and raises the likelihood of equity issuance or cost-cutting that could harm long-term growth.

Low-quality, volatile earnings

Negative TTM revenue and one-off-driven net income indicate earnings lack repeatable operational support. This volatility undermines margin sustainability and forecasting, making it difficult to rely on current profitability for reinvestment or to predict cash generation over the medium term.

Historic balance-sheet stress

A history of high leverage and past negative equity signals vulnerability to capital structure shocks. If cash flows deteriorate again, the company may face higher borrowing costs, limited access to debt markets, or dilutive equity raises, all of which can impair long-term operational stability and strategic flexibility.

Britannia Life Sciences Inc Business Overview & Revenue Model

Company Description

Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, Canada.

How the Company Makes Money

Britannia Life Sciences Inc Financial Statement Overview

Summary

Financial profile remains high-risk. Income statement quality is weak with volatile/negative TTM revenue and profitability that appears driven by non-operating items, while cash flow is meaningfully negative (operating cash flow and free cash flow), indicating ongoing cash burn. The balance sheet has improved with very low current debt versus equity, but prior periods of heavy leverage and negative equity add durability risk.

Income Statement

Results are volatile. TTM (Trailing-Twelve-Months) revenue is negative (-$4.33M) despite a very large reported growth rate, which raises quality-of-revenue concerns. Profitability is mixed: TTM shows a large positive net income ($20.49M), but margins are inconsistent (net margin negative while EBIT/EBITDA margins are positive), and the annual history includes sizable losses (e.g., 2022 and 2024) alongside profitable years (2023). Overall, earnings appear driven by non-operating items and/or one-offs rather than steady operating performance.

Balance Sheet

Leverage has improved materially over time. TTM total debt is very low ($0.18M) versus equity ($17.23M), and the latest debt-to-equity is modest, indicating balance sheet repair. However, the track record shows prior periods of heavy leverage (debt-to-equity near ~3–4x in 2022–2024) and even negative equity in 2021, highlighting historical balance sheet stress. Returns on equity are currently strong (TTM ROE ~1.82), but given earnings volatility, the sustainability of returns is a key risk.

Cash Flow

Cash generation is currently weak. TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both meaningfully negative (about -$4.10M), and free cash flow growth is also negative, pointing to rising cash burn. While some earlier years produced positive operating cash flow (notably 2022–2024), the latest shift back to outflows suggests the business may require continued financing to fund operations, which increases dilution or funding risk for a biotechnology company.

Breakdown	TTM	Mar 2025	Jun 2023	Jun 2022	Mar 2022	Mar 2021
Income Statement
Total Revenue	-4.33M	369.28K	7.57M	6.40M	7.30M	1.42M
Gross Profit	-3.01M	27.33K	4.85M	4.64M	5.26M	1.17M
EBITDA	-4.96M	-4.39M	-1.90M	6.95M	-10.77M	-1.62M
Net Income	20.49M	7.39M	-4.77M	5.08M	-15.46M	-157.16K
Balance Sheet
Total Assets	22.06M	11.61M	22.26M	23.55M	21.09M	21.45M
Cash, Cash Equivalents and Short-Term Investments	15.89M	7.85M	1.32M	2.60M	1.63M	828.32K
Total Debt	183.11K	1.86M	7.29M	8.41M	5.19M	10.55M
Total Liabilities	4.83M	5.31M	15.59M	12.49M	15.61M	18.79M
Stockholders Equity	17.23M	6.30M	2.44M	7.02M	1.35M	-202.32K
Cash Flow
Free Cash Flow	-4.10M	-2.62M	1.75M	874.41K	2.71M	-543.49K
Operating Cash Flow	-4.10M	-2.62M	2.09M	1.22M	2.80M	-586.58K
Investing Cash Flow	6.31M	11.27M	-1.44M	-3.32M	653.95K	-4.91M
Financing Cash Flow	-1.36M	-2.17M	-1.97M	2.95M	-2.58M	6.20M

Britannia Life Sciences Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLAB, the sentiment is Positive. The current price of 0.08 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.09, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.60 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BLAB.

Britannia Life Sciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	48 Neutral	C$15.41M	0.30	―	―	-3.93%	-575.24%
HEM	44 Neutral	C$15.62M	-7.36	―	―	―	-24.89%
GLOW	41 Neutral	C$9.06M	-20.15	-95.68%	―	239.98%	39.01%